Product Info

Source:
Mouse
Application:
WB 1:500-1:2000, IHC-p 1:200-1:1000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Monoclonal [AFB1823]
Specificity:
GFAP antibody detects endogenous levels of total GFAP.
RRID:
AB_2833847
Cite Format: Affinity Biosciences Cat# BF0345, RRID:AB_2833847.
Conjugate:
Unconjugated.
Purification:
Affinity-chromatography.
Storage:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

wu:fb34h11; ALXDRD; cb345; etID36982.3; FLJ42474; FLJ45472; GFAP; GFAP_HUMAN; gfapl; Glial fibrillary acidic protein; Intermediate filament protein; wu:fk42c12; xx:af506734; zgc:110485;

Immunogens

Immunogen:

Purified recombinant fragment of human GFAP expressed in E. Coli.

Uniprot:
Gene(ID):
Expression:
P14136 GFAP_HUMAN:

Expressed in cells lacking fibronectin.

Description:
This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. An additional transcript variant has been described, but its full length sequence has not been determined.
Sequence:
MERRRITSAARRSYVSSGEMMVGGLAPGRRLGPGTRLSLARMPPPLPTRVDFSLAGALNAGFKETRASERAEMMELNDRFASYIEKVRFLEQQNKALAAELNQLRAKEPTKLADVYQAELRELRLRLDQLTANSARLEVERDNLAQDLATVRQKLQDETNLRLEAENNLAAYRQEADEATLARLDLERKIESLEEEIRFLRKIHEEEVRELQEQLARQQVHVELDVAKPDLTAALKEIRTQYEAMASSNMHEAEEWYRSKFADLTDAAARNAELLRQAKHEANDYRRQLQSLTCDLESLRGTNESLERQMREQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM

PTMs - P14136 As Substrate

Site PTM Type Enzyme
T7 Phosphorylation Q96GD4 (AURKB) , P17612 (PRKACA) , Q13464 (ROCK1)
S8 Phosphorylation P17612 (PRKACA)
R11 Methylation
R12 Methylation
S13 Phosphorylation Q13464 (ROCK1) , P17612 (PRKACA) , Q96GD4 (AURKB)
Y14 Phosphorylation
S17 Phosphorylation
S38 Phosphorylation Q96GD4 (AURKB) , Q13464 (ROCK1) , P17612 (PRKACA)
K95 Acetylation
Y116 Phosphorylation
T131 Phosphorylation
T150 Phosphorylation
K154 Acetylation
Y172 Phosphorylation
K189 Acetylation
K228 Acetylation
T240 Phosphorylation
Y242 Phosphorylation
K260 Acetylation
S305 Phosphorylation
Y324 Phosphorylation
K339 Acetylation
Y349 Phosphorylation

Research Backgrounds

Function:

GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.

PTMs:

Phosphorylated by PKN1.

Subcellular Location:

Cytoplasm.
Note: Associated with intermediate filaments.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in cells lacking fibronectin.

Subunit Structure:

Interacts with SYNM (By similarity). Isoform 3 interacts with PSEN1 (via N-terminus).

Family&Domains:

Belongs to the intermediate filament family.

Research Fields

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

References

1). Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020 (PubMed: 32182488) [IF=6.7]

Application: IF/ICC    Species: Mouse    Sample: BV2 and C6 cells

Fig. 4. Effects of compounds on GFAP and Iba-1 expression in the LPS-induced astrocytes (C6, treated with 10 mg/mL of LPS) and microglia (BV2, treated with 1 mg/mL of LPS). A. Representative fluorescence microscopy images of GFAP immunostaining (Magnification  20). B. Representative fluorescence microscopy images of Iba-1 immunostaining (Magnification  40). C. Histograms show relative changes of GFAP expressed as mean ± SD of the three independent experiments (n ¼ 3). Ctrl. ¼ Control, LPS ¼ Lipopolysaccharide (10 mg/mL); 3, 13, 16 ¼ treatments by compounds 3, 13, 16 (20 mM) along with LPS (10 mg/mL). D. Histograms show relative changes of Iba-1 expressed as mean ± SD of the three independent experiments (n ¼ 3). All the data were analyzed using Image Pro Plus and expressed as a percent of LPS group values (fluorescence intensity). (#) Significant difference (##p < 0.01, ###p < 0.001) vs. control and (*) significant difference (*p < 0.05 and **p < 0.01) vs. LPS.

2). LY294002 alleviates bone cancer pain by reducing mitochondrial dysfunction and the inflammatory response. International Journal of Molecular Medicine, 2023 (PubMed: 37026522) [IF=5.4]

3). Carbenoxolone has the potential to ameliorate acute incision pain in rats. Molecular Medicine Reports, 2021 (PubMed: 34013377) [IF=3.4]

Application: IF/ICC    Species: rat    Sample:

Figure 3. |Co‑localization of Px1 and GFAP in IP model rats. Px1 (green) and GFAP (red)expression was analyzed using an immunofluorescence assay.Magnification, x200; scale bar, 10 µm. C,control group; IP, incision pain; CBX, carbenoxolone; 10panx, pannexin‑1 mimetic inhibitory peptide; Px1, pannexin 1;GFAP, glial fibrillary acidic protein

Application: IF/ICC    Species:    Sample:

Figure 3. |Co‑localization of Px1 and GFAP in IP model rats. Px1 (green) and GFAP (red) expression was analyzed using an immunofluorescence assay. Magnification, x200; scale bar, 10 µm. C, control group; IP, incision pain; CBX, carbenoxolone; 10panx, pannexin‑1 mimetic inhibitory peptide; Px1, pannexin 1;GFAP, glial fibrillary acidic protein.

4). Emodin inhibits HDAC6 mediated NLRP3 signaling and relieves chronic inflammatory pain in mice. Experimental and therapeutic medicine, 2024 (PubMed: 38144917) [IF=2.7]

5). Electroacupuncture prevents the development or establishment of chronic pain via IL-33/ST2 signaling in hyperalgesic priming model rats. Neuroscience letters, 2024 (PubMed: 38142925) [IF=2.5]

6). The effect of AQP4 on tau protein aggregation in neurodegeneration and persistent neuroinflammation after cerebral microinfarcts. Open medicine (Warsaw, Poland), 2023 (PubMed: 37873537) [IF=2.1]

Application: IF/ICC    Species: Mouse    Sample:

Figure 1 Effects of AQP4 on GFAP and p-tau aggregation. (a and b) Histology, qPCR, and Western blot assays verify adenovirus efficiency; (c and d) GFAP and AQP4 and p-tau aggregation (pSer202/pThr205, p-tau) and neuronal marker (NeuN) co-expression were evaluated by Immunofluorescence double staining. *p < 0.05 vs control. All experiments were repeated 3 times. Each group has 7 mice.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.